Immunogenic formulation of OSPC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
AssigneeBaxter Vaccine AG
InventorsIan Livey, Brian Crowe, Friedrich Dorner
Life of this patent
Estimating the term…
Abstract
A novel approach to Borrelia vaccine formulation taking into account serological, genotypic and epidemiological information by which OspC proteins from different strains of B burgdorferi are grouped together. OspC antigens are chosen in order to constitute a representative sample of such groupings, so that the resulting vaccine provides the greatest cross-protectivity with the fewest number of antigens.
Claims18
A recombinant DNA sequence comprising a nucleotide sequence selected from the group consisting of, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:21, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:39, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:45.
A recombinant DNA sequence comprising a nucleotide sequence encoding an OspC amino acid sequence selected from the group consisting of, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:16, SEQ ID NO:22 SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48.
An expression vector comprising a recombinant DNA sequence according to one of claim 1, 9, 11 or 13.
An expression vector comprising a nucleotide sequence according to one of claim 2, 10, 12 or 14.
A recombinant DNA comprising a nucleotide sequence encoding a first OspC antigen having at least 80% amino acid identity over the first 92% of a second ospc antigen having an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:24, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, wherein an antibody against said first OspC antigen recognizes said second OspC antigen.
A recombinant DNA sequence comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:19, SEQ ID NO:27, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37 and SEQ ID NO:51.
A recombinant DNA sequence comprising a nucleotide sequence encoding an OspC amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:20, SEQ ID NO:28, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, and SEQ ID NO:52.
A recombinant DNA sequence consisting essentially of a nucleotide sequence selected from the group consisting of SEQ ID NO:41 and, SEQ ID NO:43.
A recombinant DNA sequence consisting essentially of a nucleotide sequence encoding an OspC amino acid sequence selected from the group consisting SEQ ID NO:42 and SEQ ID NO:44.
A recombinant DNA sequence consisting essentially of a nucleotide sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:13, SEQ ID NO 23 and SEQ ID NO 49.
A recombinant DNA sequence consisting essentially of a nucleotide sequence encoding an OspC amino acid sequence selected from the group consisting of SEQ ID NO 8, SEQ ID NO 14, SEQ ID NO 24 and SEQ ID NO 50.
Dependencies are inferred from the claim text.